A. El Tahan

After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal

A. Mostafa, I. Kabbash, M. Alboraie, 2018, Journal of clinical laboratory analysis (Print).

Letter: concordance of SVR4 and SVR12 following direct‐acting anti‐viral treatment in Egypt

A. Fontanet, G. Esmat, M. Elbadry, 2018, Alimentary pharmacology & therapeutics.

Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes

I. Kabbash, G. Esmat, W. Doss, 2018, American journal of therapeutics.

High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results

W. Doss, M. Alboraie, H. Omar, 2019, Journal of medical virology.

Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study.

W. Doss, S. Zaky, F. El-Raey, 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C‐infected Egyptian cohort: A comparative analysis

A. Fontanet, G. Esmat, N. Youssef, 2018, Journal of viral hepatitis.

Herpes Zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: A case series.

R. Mahdy, N. Youssef, M. El kassas, 2017, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.